| Line 3: |
Line 3: |
| | Genital warts are most commonly associated with HPV–6 and HPV–11. HPV types 16 and 18 together are found in about 70 percent of cervical cancers. <ref>National Cancer Institute: Human Papillomaviruses and Cancer: Questions and Answers [http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref> | | Genital warts are most commonly associated with HPV–6 and HPV–11. HPV types 16 and 18 together are found in about 70 percent of cervical cancers. <ref>National Cancer Institute: Human Papillomaviruses and Cancer: Questions and Answers [http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref> |
| | | | |
| − | Only about 3% of women have active infections at any given time with one or more of these four types of HPV (Types 6, 11, 16, 18) targeted by the vaccine.<ref name="JAMA">This was confirmed by a study published February 28, 2007 in the Journal of the American Medical Association, JAMA 297(8):813-819, February 28, 2007. "HPV vaccine types 6 and 11 (low-risk types) and 16 and 18 (high-risk types) were detected in 3.4% of female participants ...."[http://jama.ama-assn.org/cgi/content/full/297/8/813]</ref> The vaccine is very expensive and has been associated with severe adverse reactions, including paralysis.<ref>[http://www.telegraph.co.uk/health/healthnews/3758983/Schoolgirl-12-paralysed-after-receiving-cervical-cancer-jab.html 12-year-old paralyzed]</ref> | + | Only about 3% of women are infected in their lifetime by these four types of HPV (Types 6, 11, 16, 18) targeted by the vaccine.<ref name="JAMA">This was confirmed by a study published February 28, 2007 in the Journal of the American Medical Association, JAMA 297(8):813-819, February 28, 2007. "HPV vaccine types 6 and 11 (low-risk types) and 16 and 18 (high-risk types) were detected in 3.4% of female participants ...."[http://jama.ama-assn.org/cgi/content/full/297/8/813]</ref> The vaccine is very expensive and has been associated with severe adverse reactions, including paralysis.<ref>[http://www.telegraph.co.uk/health/healthnews/3758983/Schoolgirl-12-paralysed-after-receiving-cervical-cancer-jab.html 12-year-old paralyzed]</ref> |
| | | | |
| | The HPV vaccine does not protect against other sexually transmitted diseases (e.g., [[chlamydia]], [[herpes]], [[hepatitis]], [[trichomoniasis]], [[gonorrhea]], [[syphilis]], [[HIV]], [[AIDS]], etc.), and the vaccine is not recommended for use in pregnant women or girls.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> | | The HPV vaccine does not protect against other sexually transmitted diseases (e.g., [[chlamydia]], [[herpes]], [[hepatitis]], [[trichomoniasis]], [[gonorrhea]], [[syphilis]], [[HIV]], [[AIDS]], etc.), and the vaccine is not recommended for use in pregnant women or girls.<ref>http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf</ref> |
| | | | |
| | "Gardasil had three times the number of Emergency Room visits [than associated with the meningitis vaccine] - more than 5,000. Reports of side effects were up to 30 times higher with Gardasil."<ref>http://www.cbsnews.com/stories/2009/02/06/eveningnews/main4781658.shtml?source=RSSattr=HOME_4781658</ref> | | "Gardasil had three times the number of Emergency Room visits [than associated with the meningitis vaccine] - more than 5,000. Reports of side effects were up to 30 times higher with Gardasil."<ref>http://www.cbsnews.com/stories/2009/02/06/eveningnews/main4781658.shtml?source=RSSattr=HOME_4781658</ref> |
| − |
| |
| − | In spite of this, post-licensure surveillance studies have established that the safety record of the HPV vaccine is on par with that of most childhood vaccinations. The reported rate of adverse effects was 0.05% (about 5 in 10,000). The most commonly reported adverse effects were fainting and rash.<ref>http://jama.ama-assn.org/content/302/7/750.full</ref> The majority of patients exhibiting hypersensitivity to the first dose tolerated the subsequent doses with no reported symptoms.<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769055/?tool=pmcentrez</ref>
| |
| | | | |
| | In a remarkable move, a researcher for the HPV vaccine declared, "Public Should Receive More Complete Warnings":<ref>http://www.cbsnews.com/stories/2009/08/19/cbsnews_investigates/main5253431.shtml</ref> | | In a remarkable move, a researcher for the HPV vaccine declared, "Public Should Receive More Complete Warnings":<ref>http://www.cbsnews.com/stories/2009/08/19/cbsnews_investigates/main5253431.shtml</ref> |